EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metastatic EGFR-Mutant Lung Adenocarcinoma Patients: A Safety and Efficacy Analysis of First- and Third-Generation EGFR-TKIs

Suha Ali Hammed, Alaa Fadhil Alwan

Middle Eastern Cancer and Oncology Journal · 2025

DOI: 10.61706/mecoj160189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Middle Eastern Cancer and Oncology Journal, 2025. Verfasst von Suha Ali Hammed und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of metastatic non-small cell lung cancer (NSCLC), the phenomenon of resistance to therapeutic interventions is a prevalent occurrence, particularly in cases involving tumors that harbor epidermal growth factor receptor (EGFR) mutations. Tyrosine kinase inhibitors (TKIs) directed at the epidermal growth factor receptor have transformed first-line care. The objective of this study is to compare the safety and effectiveness of first-generation (gefitinib) versus third-generation (osimertinib) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treatment-naïve patients with metastatic epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. A cross-sectional cohort study was conducted at the Oncology Teaching Hospital in Baghdad from 2023 to 2024. The study included 40 adults with molecularly confirmed epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), who received first-line gefitinib or osimertinib treatment. The tumor response was evaluated using the RECIST v1.1 criteria at the three-cycle interval, and the adverse events (AEs) were assessed according to the CTCAE v4.03 scale. The PFS was estimated using Kaplan–Meier methods. The study demonstrated that osimertinib resulted in a substantially longer mean progression-free survival (18.2 months; 95% CI: 13.97–25.03) in comparison to gefitinib (7.1 months; 95% CI: 4.54–12.46; p

Zitieren

APA

Hammed, S. A., & Alwan, A. F. (2025). Metastatic EGFR-Mutant Lung Adenocarcinoma Patients: A Safety and Efficacy Analysis of First- and Third-Generation EGFR-TKIs. Middle Eastern Cancer and Oncology Journal. https://doi.org/10.61706/mecoj160189

Vancouver

Hammed SA, Alwan AF. Metastatic EGFR-Mutant Lung Adenocarcinoma Patients: A Safety and Efficacy Analysis of First- and Third-Generation EGFR-TKIs. Middle Eastern Cancer and Oncology Journal. 2025. doi:10.61706/mecoj160189

BibTeX
@article{Hammed2025,
  author = {Hammed, Suha Ali and Alwan, Alaa Fadhil},
  title = {Metastatic EGFR-Mutant Lung Adenocarcinoma Patients: A Safety and Efficacy Analysis of First- and Third-Generation EGFR-TKIs},
  journal = {Middle Eastern Cancer and Oncology Journal},
  year = {2025},
  doi = {10.61706/mecoj160189}
}
Kostenlos starten →